GlassScriptPhysician profile
Mandeep Gill
NPI 1215912126
$4,572.02
in general payments reported to CMS, 2019-2025
23 companies · $1,829 in 2025
The $1,829 reported for 2025 was more than what 88% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $239 · 2020: $89.62 · 2021: $542 · 2022: $104 · 2023: $1,093 · 2024: $677 · 2025: $1,829.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,512 · Education: $85.63.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,512.27 |
| Education | $85.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $756.96 | 2021-2025 | Lokelma, Farxiga |
| Amgen INC. | $658.69 | 2023-2025 | Tavneos, Krystexxa |
| Travere Therapeutics, INC. | $442.04 | 2023-2025 | |
| Horizon Therapeutics Plc | $434.48 | 2021-2023 | Krystexxa |
| Abbott Laboratories | $386.29 | 2025 | Freestyle Libre 3 |
| Calliditas Therapeutics US INC. | $229.71 | 2025 | Tarpeyo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $201.08 | 2023-2025 | Jardiance |
| Fresenius USA Marketing, INC. | $186.76 | 2020-2025 | Velphoro, Velphoro |
| Mallinckrodt Hospital Products INC. | $176.36 | 2021-2025 | Acthar, Terlivaz |
| Novartis Pharmaceuticals Corporation | $169.51 | 2024-2025 | |
| Opko Pharmaceuticals, LLC | $158.76 | 2021-2023 | Rayaldee |
| Otsuka America Pharmaceutical, INC. | $154.10 | 2023-2025 | Jynarque |
| Mallinckrodt Enterprises LLC | $124.71 | 2019 | |
| Alexion Pharmaceuticals, INC. | $113.96 | 2019 | |
| Ani Pharmaceuticals, INC. | $81.06 | 2023 | Purified Cortrophin Gel |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $74.14 | 2025 | Spravato |
| Akebia Therapeutics INC | $53.15 | 2025 | Vafseo |
| Bayer Healthcare Pharmaceuticals INC. | $52.83 | 2023-2025 | |
| Daiichi Sankyo INC. | $26.94 | 2023 | Injectafer |
| Scpharmaceuticals INC. | $26.14 | 2025 | |
| Ardelyx, INC. | $24.16 | 2024 | Ibsrela |
| Aurinia Pharma U.S., INC. | $23.25 | 2024 | Lupkynis |
| Glaxosmithkline, LLC. | $16.94 | 2025 | Arexvy, Shingrix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mandeep Gill listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.